365P Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Annals of Oncology(2022)
摘要
Osimertinib (osi) is a third-generation EGFR tyrosine kinase inhibitor (TKI) with antitumor activity in non-small cell lung cancer (NSCLC) against activating EGFR and T790M mutation. The incidence of oligo-PD on first-line osi is unknown.
更多查看译文
关键词
cancer,first-line,mutation-positive,non-small
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要